Company / Shareholders' Equity
KYNTRA BIO, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$30.0M
FY2025
5-year range
-$225.6M / $422.2M
FY2021-FY2025
Trend
+86.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
KYNTRA BIO, INC. reports negative total equity of -$30M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$30M in FY2025.
Improved from -$204M to -$30M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 86.7% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$30.0M | +86.7% |
| FY2024 | -$225.6M | -10.5% |
| FY2023 | -$204.2M | -852.0% |
| FY2022 | -$21.4M | -105.1% |
| FY2021 | $422.2M | +0.0% |
| FY2020 | $422.2M | -18.2% |
| FY2019 | $516.1M | +1.4% |
| FY2018 | $509.2M | -9.6% |
| FY2017 | $563.2M | +261.4% |
| FY2016 | $155.8M | -12.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026